Abstract:The advent of anti-TNF agents as the first approved targeted therapy in the treatment of inflammatory bowel disease (IBD) patients has made a major impact on our existing therapeutic algorithms. They have not only been approved for induction and maintenance treatment in IBD patients, but have also enabled us to define and achieve novel therapeutic outcomes, such as combination of clinical symptom control and endoscopic remission, as well as mucosal healing. Nevertheless, approximately one third of treated patients do not respond to initiated anti-TNF therapy and these treatments are associated with sometimes severe systemic side-effects. There is therefore the currently unmet clinical need do establish predictive markers of response to identify the subgroup of IBD patients, that have a heightened probability of response. There have so far been approaches from different fields of IBD research, to descry markers that would empower us to apply TNF-inhibitors in a more rational manner. These markers encompass findings from disease-related and clinical factors, pharmacokinetics, biochemical markers, blood and stool derived parameters, pharmacogenomics, microbial species, metabolic compounds, and mucosal factors. Furthermore, changes in the intestinal immune cell composition in response to therapeutic pressure of anti-TNF treatment have recently been implicated in the process of molecular resistance to these drugs. Insights into factors that determine resistance to anti-TNF therapy give reasonable hope, that a more targeted approach can then be utilized in these non-responders. Here, IL-23 could be identified as one of the key factors determining resistance to TNF-inhibitors. Growing insights into the molecular mechanism of action of TNF-inhibitors might also enable us to derive critical molecular markers that not only mediate the clinical effects of anti-TNF therapy, but which level of expression might also correlate with its therapeutic efficacy. In this narrative review, we present an overview of currently identified possible predictive markers for successful anti-TNF therapy and discuss identified molecular pathways that drive resistance to these substances. We will also point out the necessity and difficulty of developing and validating a diagnostic marker concerning clinically relevant outcome parameters, before they can finally enter daily clinical practice and enable a more personalized therapeutic approach.

Antibodies targeting the tumor necrosis factor (TNF) -like ligand 1A (TL1A) in Inflammatory Bowel Disease – a new kid on the (biologics) block?

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations

Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD

Targeting of Costimulatory Molecules As a Therapeutic Approach in Inflammatory Bowel Disease

Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials

Anti‐TNF and Immunosuppressive Combination Therapy is Preferential to Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease: A Systemic Review and Meta‐analysis

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

Novel Targeted Therapies for Inflammatory Bowel Disease

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

Crohn's targeted therapy: myth or real goal?

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?

Immunotherapy in inflammatory bowel disease: Novel and emerging treatments

Immune Cell Therapy in IBD

Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

Comparison of modified gunsight suture technique and traditional interrupted suture in enterostomy closure

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

Predictive biomarkers for anti-TNF alpha therapy in IBD patients

Novel Agents in the Future: Therapy Beyond Anti-Tnf Agents in Inflammatory Bowel Disease.